GE HealthCare (GEHC) Q4 2025 earnings review
Top-Line Acceleration Meets Margin Compression
GE HealthCare closed FY25 with its strongest revenue growth of the year (+4.8% organic), driven by robust demand in the U.S. and EMEA. However, the cost of doing business has spiked—tariffs and mix shifts compressed Adjusted EBIT margin by 200 basis points to 16.7%. While management successfully drove volume, it came at the expense of profitability in the quarter. The FY26 outlook is constructive, guiding for margin expansion (50-80 bps) and ~10% EPS growth, suggesting the worst of the tariff shock is now baselined.
🐂 Bull Case
PDx continues to be the crown jewel of growth, delivering 12.7% organic growth in Q4. Despite a margin dip, it remains highly profitable (29.6% margin). High recurring revenue here provides a safety net against equipment cycles.
Total orders grew 2.0% organically with a book-to-bill of 1.06x, signaling that demand remains healthy despite pricing pressures. The backlog is at record levels, providing visibility into FY26.
🐻 Bear Case
Every single segment reported YoY margin contraction in Q4. Patient Care Solutions (PCS) collapsed 380 bps to single digits (9.0%), and even the high-flying PDx segment dropped 330 bps. This indicates systemic cost pressure (tariffs) rather than isolated execution issues.
Patient Care Solutions is the only segment shrinking organically (-1.1%) while simultaneously hemorrhaging margin. It is currently a drag on the broader portfolio.
⚖️ Verdict: ⚪
Neutral. Top-line momentum is undeniable and the 2026 guidance implies a recovery in profitability. However, the widespread margin compression in Q4 is a "show-me" risk—management must prove they can pass through tariff costs effectively in the new fiscal year.
Key Themes
Tariffs Crushing Profitability
The tariff narrative has shifted from a risk to a realized hit. Adjusted EBIT margin fell 200 bps to 16.7% in Q4, and Adjusted EPS was flat (-$0.01) despite 7% revenue growth. Management explicitly cited tariff expense as a primary driver. While 2026 guidance assumes lower tariff impact, the Q4 actuals show the company is currently absorbing significant costs.
Pharmaceutical Diagnostics (PDx) Strength
PDx remains the standout growth driver, posting +22.3% reported and +12.7% organic revenue growth in Q4. This segment is benefiting from volume and price, likely driven by contrast media demand and new agent adoption (Flyrcado/Vizamyl). Even with a margin dip, it generates nearly 30% operating margins, funding the rest of the business.
Patient Care Solutions (PCS) Laggard Status
PCS is flashing red. Organic revenue declined 1.1% in Q4 (the only segment to shrink), and segment EBIT fell nearly 30% YoY. The margin profile (9.0%) is significantly dilutive to the group. This segment has faced 'product holds' in prior quarters (Q3), and the Q4 data suggests the turnaround is not yet gaining traction.
Intelerad Acquisition
GEHC announced the planned $2.3 billion acquisition of Intelerad during Q4. This move targets the high-margin enterprise imaging software space (cloud-enabled). While closing is expected in H1 2026, it signals a strategic shift toward SaaS-like revenue streams to buffer against hardware cyclicality and tariff exposure.
Capital Allocation & Cash Flow
Free cash flow conversion dipped to 72% (vs 95% operating cash conversion) due to CapEx investments. The company repurchased $200M in shares in 2025—a modest amount given the market cap—but retains significant firepower with $4.5B in cash. The Intelerad deal shows the priority is clearly M&A over aggressive buybacks.
Other KPIs
Accelerating. Organic growth hit +5.3%, up from +4.0% in Q3 and +1.0% in Q2. As the largest segment, this acceleration is critical for the overall top-line beat.
Decelerating. Down slightly from $1.55B in FY24. The decrease was driven by tariff impacts, partially offset by lower interest/tax payments. Guidance for 2026 sees this rebounding to ~$1.7 billion.
Stable. Orders grew 2.0% organically in Q4. While slower than Q3's 6% growth, keeping book-to-bill above 1.0 ensures revenue visibility entering 2026.
Guidance
Stable. The midpoint (3.5%) is exactly in line with FY25 actuals (3.5%). Management expects the current momentum to sustain but isn't promising a massive acceleration.
Accelerating. Implies a 50-80 bps expansion vs FY25 (15.3%). This is the critical 'prove it' metric—management is betting on tariff mitigation and volume leverage to reverse the Q4 contraction trend.
Accelerating. Midpoint growth of ~10% vs FY25 ($4.59). This outpaces revenue growth, driven by margin expansion and tax rate management (guided 20-21%).
Accelerating. implies ~13% growth from FY25 ($1.5B). Suggests improved working capital efficiency or lower one-time tariff cash outlays.
Key Questions
PCS Turnaround Timeline
Patient Care Solutions margins remain in single digits (9.0%) and revenue is shrinking. With a new leader in place, when do you expect this segment to return to accretive growth and double-digit margins?
Pricing Power vs Tariffs
Q4 margins compressed 200 bps despite volume growth. How much of the projected 2026 margin expansion (50-80 bps) relies on price increases versus internal cost/supply chain actions?
Intelerad Synergies
Regarding the $2.3B Intelerad acquisition: What is the expected accretion timeline, and does this signal a broader shift to prioritize software M&A over device hardware?
China Market Dynamics
With organic revenue up 4.8% globally, what was the specific performance in China this quarter? Are we seeing the impact of stimulus measures, or does the market remain a drag on global results?